Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|January 28, 2009
CRF Announces New Investor
Advertisement
CRF Inc. Announces smac | partners as New Investor
Strong year for CRF Inc. with new client wins and new global headquarters
Lansdale, PA-January 26, 2009: CRF Inc. (CRF), a leading global provider of electronic Patient Reported Outcomes (ePRO) and wireless data collection solutions for the Life Science Industry, today announced it has a new investor, smac | partners.
This announcement adds to a strong year of growth for CRF Inc., with several high profile new client wins for CRF Inc., in addition to its repeat business wins and the appointment of a new CEO, Rachael King.
Chief Executive, Rachael King said, "smac | partners will make a great addition to the CRF Inc. investment board. It has an impressive operational background and an exceptional global network and will add value to the strong investment team already with CRF Inc. 2008 has been an exceptional year for CRF Inc. and we look forward to continuing this innovation and growth throughout 2009."
smac | partners is a venture capital investor specialized in the ICT segment and is based in Munich, Germany. Oliver Kolbe, Managing Partner and Co-Founder of smac | partners, commented, "CRF is in a strong market position and its innovative approach to its solutions fits in perfectly with the smac | partners investment strategy, especially with the unique wireless service solution CRF Inc. offers to its clients."
In 2008 CRF also finalized its new global headquarters in Lansdale, PA, centralizing its services within North America.
About CRF Inc.
CRF Inc. ("CRF") is a leading global provider of electronic Patient Reported Outcomes ("ePRO") and wireless data collection solutions for the Life Science Industry. Through innovative technology and a thorough understanding of drug development and mobile computing, CRF is driving the change to safer and more efficient paper-free clinical trials. CRF's technology has been used by more than 180,000 patients across 59 countries in 60 languages for 45 indications. The company has demonstrated one of the
industry's highest patient compliance rates-an average 90% compliance through Phase I, II, III and IV clinical trials.
CRF's award-winning product, the TrialMaxR suite, is a flexible and configurable ePRO technology that provides real-time patient monitoring, outstanding data accuracy and increased safety through compliance. The TrialMax application's unique features enable clinical trial sponsors to rapidly collect valuable data and conduct complex clinical trials with greater flexibility than other ePRO solutions. CRF's experience, combined with its dedication to achieving the highest quality and most responsive customer service, has made the company one of the life science industry's most trusted partners.
For more information, please visit
TrialMaxR, TrialCollectorR, TrialIntegratorR, TrialManagerR and TrialStudioR are registered trademarks of CRF Inc. All rights reserved. TrialLibraryT and other CRF product references are either a trademark or service mark of CRF Inc. All rights reserved. All other trademarks and/or service marks are the property of their respective owners.
About smac | partners
smac | partners is an international Venture Capital company, based in Munich, focusing on investments in young, fast growing companies in the IT-industry and telecommunication. smac partners is one of the few Venture Capital companies with long investment, management and exit experience in USA, China, India, Europe and Israel.
Advertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
2
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
3
ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5